A Phase I Study to Evaluate the Safety and Pharmacokinetics of R306465 in Subjects With Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 主要终点
- Determine the safety and maximum tolerated dose of R306465 when given as a daily oral dose during 3 weeks followed by a 1 week recovery period. Study the absorption, break down and elimination of R306465 following oral administration.
研究概览
简要总结
The purpose of this study is to assess the safety of R306465 (a drug in development for cancer) in patients with advanced cancer on the maximum dose that can be tolerated. Also, the absorption, breakdown and elimination of the drug will be studied.
详细描述
R306465, a histone deacetylase (HDAC) inhibitor, is a new drug in development for cancer. In this study, the safety (the effect on the body) of R306465 in patients with advanced cancer will be studied and the maximum dose that can be tolerated by these patients will be determined. The absorption, break down, and elimination of the drug will be studied. Antitumor activity of R306465 will be evaluated.
R306465 will be administered in a continuous regimen for 21 days followed by a 1-week rest period, which constitutes a 28-day treatment cycle. The dose of R306465 will start low and will be increased during the study in groups of 3 to 6 patients. If a group of patients does not have severe side effects, the next group of patients will get a higher dose. The dose will increase until some patients have severe side effects. The dose will then be decreased to a dose level where severe side effects are observed in less than 1/3 of patients. The amount of R306465 in the blood will be measured and the effect on the disease will be evaluated in all patients.
Patients will be screened for eligibility within 4 weeks before study treatment is given. The duration of treatment will depend on adverse effects and whether there is benefit from the treatment.
The design of a cycle may be adjusted during the course of the study as guided by clinical observations. The dosing regimen may be adjusted as guided by information on how rapidly your body breaks down and eliminates the study drug. Patients will be informed if there are changes in the design of a cycle or the dosing regimen.
During the first treatment cycle, patients are required to stay in the hospital for at least 3 nights. In addition there are 6 daytime visits during Cycles 1 and 2 (combined) that may take up to 4 hours after the morning dose. From Cycle 3 onwards, there are only 2 daytime visits per treatment cycle, and these visits usually take up less time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed solid malignancy that is metastatic or unresectable, and for which standard curative or palliative measures does not exist or are no longer effective
- •Performance status (based on the Eastern Cooperative Oncology Group assessments) of <= 2
- •Life expectancy > 3 months
- •Adequate gastrointestinal absorption status
- •Must meet protocol-defined criteria for lab assessments and adequate bone marrow, liver, and kidney function.
排除标准
- •Known central nervous system metastases
- •Chemotherapy, radiotherapy, immunotherapy within 4 weeks before study drug administration or incomplete recovery from preceding surgery
- •Previous participation in a clinical study with histone deacetylase (HDAC) inhibitor or another investigational anticancer agent within 4 weeks of dosing with R306465
- •Patient has signs and symptoms of acute infection requiring systemic therapy
- •Patient is not recovered from reversible toxicity of prior anticancer therapy.
结局指标
主要结局
Determine the safety and maximum tolerated dose of R306465 when given as a daily oral dose during 3 weeks followed by a 1 week recovery period. Study the absorption, break down and elimination of R306465 following oral administration.
次要结局
- Investigate the effect of food on oral administration of R306465. Evaluate the antitumor activity of R306465 in patients with measurable cancer.